
STAT+: Lawmakers want U.S. biotech to outcompete China
Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:
Recent stories from STAT Biotech.

Lawmakers leading the congressional BIOTech Caucus say Washington needs to act in the sector — and fast:

Two telehealth giants rolled out peptide programs this week after HHS made it easier for compounding pharmacies to offer drugs like BPC-157.

Merck and Isomorphic Labs said they are entering into a research collaboration to discover small molecule candidates in oncology.

Did the biotech company Erasca find a more potent, better-tolerated pan-RAS cancer drug than Revolution Medicines?

STAT tackles the most important questions about the FDA's uncertain future.

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

Flagship is putting up 100 million pounds to start “AI-native platform companies" focused on human and planetary health in the U.K.:

Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.

Researchers are seeking a sickle cell treatment as effective as gene therapy, without the drawbacks. This entrepreneur thinks he might have one.

An unexpected patient death rattled researchers who sought to pierce the blood-brain barrier. Now some think they have a better way of mitigating risks.

The supplement NAC has been widely available for years, but exists in a legal gray area.

Biotech is having a good year, though you wouldn't necessarily know it from how investors are treating positive clinical data.

A psychedelic drug from Helus Pharma improved depression in a study, but is facing safety questions with a number of serious adverse events reported.

CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.

Versant Ventures, Eli Lilly, and a handful of other investors will pour $100 million into a new startup devoted to solving a thorny gene therapy challenge.

A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.

The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.

The Trump administration will funnel up to $4.9 million into supporting research into ibogaine, a psychedelic that’s drawn interest as a potential treatment for PTSD and addiction.

With a new deal announced this week, the relationship between Eli Lilly and a telehealth company that markets GLP-1s is expected to grow more complicated.

Pfizer spent up to $10 billion to buy Metsera last year. Now, it’s bringing in private equity behemoth Blackstone to help pay for the deal.

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

Biogen is expected to soon release the results of pivotal clinical trials of an experimental therapy for lupus.

Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:
The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”
PepGen says its candidate is correcting more of the genetic stutter found in myotonic dystrophy type 1.

Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.

The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that's sometimes referred to as an "eye stroke."

For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…

Once again, a hot new technology that was supposed to speed up drug research has fallen flat.

The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.